Pharmacy · Independent exam preparation
Pharmacists Licensure Examination: Philippine Preparation Guide Study Guide
Practise pharmaceutical calculations, medicinal and plant chemistry, drug mechanisms, formulation decisions, instrumentation and quality assessment across the six weighted subjects.
By CertMedbry · Updated 28 October 2026
Calculate concentrations, connect chemical structure with drug behavior, distinguish therapeutic mechanisms, assess dispensing decisions and interpret analytical results. This selective 60-concept guide develops representative foundations across all six PRC subjects. The official PRC outline remains the full scope; these lessons do not exhaust every listed topic.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and jurisdiction does this guide cover?
The Pharmacists Licensure Examination administered by the Philippine Professional Regulation Commission through the Professional Regulatory Board of Pharmacy. The workbook label 'Philippines Pharmacist Licensure Examination' refers to this examination. It concerns pharmacist licensure in the Philippines.
PRC: Program of the Pharmacists Licensure Examination, October 15 and 16, 2026
Which outline and dates support this guide?
The governing reference is the official program for October 15–16, 2026, approved July 21, 2026. It establishes subject-level scope and weights for that sitting. It does not identify a separate general syllabus effective date or detailed TOS revision number. These lessons should not be treated as an exhaustive competency list.
PRC: Program of the Pharmacists Licensure Examination, October 15 and 16, 2026 · PRC: 2026 Schedule of Examination
What are the official subject weights?
Pharmaceutical Chemistry: 20%; Pharmacognosy/Biochemistry: 15%; Practice of Pharmacy: 17.5%; Pharmacology-Pharmacokinetics: 15%; Pharmaceutics: 17.5%; Quality Control/Quality Assurance: 15%. The 60 concepts allocate 12, 9, 11, 9, 10 and 9 lessons respectively. Each 20-item learning set allocates 4, 3, 4, 3, 3 and 3 items, approximating the published weights with whole items.
PRC: Program of the Pharmacists Licensure Examination, October 15 and 16, 2026
How many questions are scored, and are there pretest questions?
An official total question count and scored-versus-pretest breakdown are not established by the cited examination evidence. The 20 questions here are a learning set and do not represent the examination's official length or scoring structure.
PRC: Program of the Pharmacists Licensure Examination, October 15 and 16, 2026
What duration, delivery method, adaptivity and item styles are verified?
The official sitting spans October 15 and 16, 2026. A total testing duration, delivery method, adaptive design and item-style specification are not established by the cited examination evidence. These drills use four-option single-best-answer questions for study; they do not claim to reproduce the official interface or examination format.
PRC: Program of the Pharmacists Licensure Examination, October 15 and 16, 2026 · PRC: 2026 Schedule of Examination
Do the April and October examinations represent different licensure pathways?
The official schedule identifies April 18–19 and October 15–16 as separate 2026 sittings of the same Pharmacists Licensure Examination. This guide uses the October program. Candidates preparing for a later sitting should check that sitting's PRC program and any applicable TOS.
PRC: 2026 Schedule of Examination · PRC: Program of the Pharmacists Licensure Examination, October 15 and 16, 2026 · PRC Downloads
These independently authored learning materials support preparation for Philippine pharmacist professional licensure. They are not official PRC questions. Scientific references support the lessons; foreign guidance and product labels do not establish Philippine legal requirements.
Outline used: Verified against the official October 15–16, 2026 examination program, dated July 21, 2026, which publishes the current subject-level scope and weights. The workbook label 'Philippines Pharmacist Licensure Examination' maps to PRC's 'Pharmacists Licensure Examination'; the assigned slug is preserved. A detailed current TOS was not successfully opened.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Pharmaceutical Chemistry20%
1.Which acid–base pair can form a buffer?
A buffer contains appreciable amounts of a weak acid and its conjugate base, or a weak base and its conjugate acid. The partners differ by one proton. Added hydrogen ions react mainly with the basic partner, while added hydroxide reacts mainly with the acidic partner. Identify both members and their amounts before using a buffer equation; simply combining an acid with any salt does not establish buffering.
Apply it
A proposed formulation contains acetic acid and sodium acetate. Identify acetate as the proton-accepting partner and acetic acid as the proton donor. Replacing acetate with sodium chloride removes the relevant conjugate-base reservoir.
Common pitfall: A weak acid alone is not equivalent to a useful conjugate-pair buffer. Its pH may change substantially when a relatively small quantity of base is added.
2.How does the conjugate-base ratio determine buffer pH?
For a suitable weak-acid buffer, the Henderson–Hasselbalch relationship is pH = pKa + log([A−]/[HA]). Equal concentrations give pH equal to pKa; a tenfold excess of conjugate base raises pH by approximately one unit. Use concentrations after reaction and mixing. This approximation becomes less reliable when dissociation or nonideal behavior materially changes the assumed concentrations.
Apply it
A buffer has pKa 6.2 and a conjugate-base-to-acid ratio of 10. Its estimated pH is 7.2. If the ratio becomes 0.1, the estimated pH falls to 5.2.
Common pitfall: Reversing acid and base in the logarithmic ratio reverses the predicted pH shift. Check whether the more abundant partner should make the mixture more acidic or basic.
3.How does dilution affect buffer capacity and neutralizing reserve?
Diluting both buffer partners equally approximately preserves their ratio and initial pH but lowers buffer capacity per unit volume. Equal-volume aliquots of concentrated and diluted buffers contain different amounts of the conjugate pair: the diluted aliquot contains fewer buffer moles. Equal acid additions therefore consume a larger fraction of its available base. Diluting an entire preparation while retaining all its buffer moles preserves its total stoichiometric neutralizing reserve, distributed through a larger volume.
Apply it
Compare 10 mL of an acetate buffer with 10 mL of its tenfold dilution. Add the same small amount of HCl without exhausting either buffer. The diluted aliquot undergoes the larger pH shift because it contains one-tenth the buffer moles.
Common pitfall: Do not infer a reduced total reserve merely from dilution. Distinguish equal-volume aliquots from the entire diluted preparation containing all the original buffer moles.
4.How does acid-catalyzed ester hydrolysis proceed?
Acid-catalyzed ester hydrolysis converts an ester and water into a carboxylic acid and an alcohol through nucleophilic acyl substitution. Protonation increases carbonyl electrophilicity, facilitating water attack and subsequent bond rearrangements. The acid catalyst is regenerated rather than consumed stoichiometrically. Because the process is reversible, excess water favors hydrolysis. Recognizing an ester linkage helps explain why aqueous acidic conditions can alter the stability of an ester-containing substance.
Apply it
An ester-containing model compound is heated in excess water with a catalytic amount of acid. Predict a carboxylic acid and alcohol as products, and recognize that abundant water helps drive the equilibrium toward cleavage.
Common pitfall: Do not describe the acid catalyst as the source of an irreversible reaction. Acidic ester hydrolysis remains an equilibrium process under ordinary reaction conditions.
5.Why does basic ester hydrolysis produce a carboxylate?
In basic ester hydrolysis, hydroxide attacks the ester carbonyl and the reaction ultimately produces an alcohol and a carboxylate ion. Deprotonation of the initially formed carboxylic acid favors product formation, making saponification effectively irreversible under the basic conditions. A separate acidic workup converts the carboxylate into its carboxylic acid. Track the reaction medium when naming products because protonation state is part of the chemical answer.
Apply it
Ethyl acetate reacts with aqueous sodium hydroxide. Before acidic workup, identify ethanol and acetate as the principal organic products. Adding sufficient acid afterward converts acetate into acetic acid.
Common pitfall: Writing only the neutral carboxylic acid ignores the basic reaction medium. Acidification is a separate step with a distinct proton-transfer consequence.
6.How does a medicinal-chemistry scaffold differ from a product's vehicle?
A scaffold describes the central molecular framework of a drug. Theophylline is a methylxanthine, structurally identified as 1,3-dimethylxanthine. In the cited injection, dextrose is a separate hexose-sugar component of the vehicle; it is not part of theophylline's molecular scaffold. Distinguishing active-molecule structure from formulation composition prevents attributing a vehicle's chemical identity to the drug itself.
Apply it
When examining theophylline in 5% dextrose injection, classify theophylline as a methylxanthine and dextrose as the glucose-containing vehicle component. The product contains both substances without making them one covalent molecule.
Common pitfall: A product name listing two ingredients does not establish that those ingredients form a new drug scaffold or share the same pharmacologic role.
7.Which tetrahedral carbon is a stereogenic center?
A common tetrahedral stereogenic center is a carbon attached to four different substituents. Compare complete substituent paths rather than only the first attached atom; two groups beginning with carbon can differ farther along their structures. A carbon bearing two identical groups does not meet this criterion. This structural test helps identify this form of chirality before assigning configuration.
Apply it
The alcohol-bearing carbon in butan-2-ol is attached to hydrogen, hydroxyl, methyl and ethyl groups, so it is stereogenic. The corresponding carbon in propan-2-ol has two methyl groups and fails the test.
Common pitfall: A carbon drawn at a branching point is not automatically stereogenic. Identical substituents remain identical when drawn in different directions.
OpenStax Organic Chemistry: Enantiomers and the Tetrahedral Carbon
8.Why can enantiomers interact differently with biological targets?
Enantiomers have identical connectivity but are nonsuperimposable mirror images. A biological binding site has a three-dimensional arrangement of interaction points, so the two spatial arrangements need not fit it equally. This provides a structural basis for stereoselective drug recognition. It does not establish which enantiomer is more active for an unspecified drug. Equal amounts of enantiomers can also cancel their opposite optical rotations without becoming achiral molecules.
Apply it
Two enantiomers share a molecular formula and connectivity but differ in measured target binding. Their spatial fit can explain the difference. A racemic mixture may show zero net optical rotation despite containing both chiral structures.
Common pitfall: Neither a configuration designation nor the sign of optical rotation independently predicts therapeutic activity. Compound-specific evidence is required.
OpenStax Organic Chemistry: Enantiomers and the Tetrahedral Carbon
9.How do metabolic structural changes affect interpretation of a drug and its metabolites?
Theophylline undergoes demethylation and hydroxylation. Demethylation removes a methyl substituent, whereas hydroxylation introduces an oxygen-containing modification; these are different transformations from ester hydrolysis. Metabolites also need not have the same activity as the parent. The cited label identifies caffeine and 3-methylxanthine as pharmacologically active metabolites, with 3-methylxanthine having substantially less activity than theophylline.
Apply it
A scheme converts theophylline to 3-methylxanthine. Recognize demethylation rather than cleavage of an ester bond. Evaluate the metabolite's activity and exposure separately from those of the parent drug.
Common pitfall: Do not assume that every metabolite is inactive or that the parent and metabolite have equal potency. Structural change alone does not supply a quantitative activity prediction.
10.Which reactant is the oxidizing agent?
Oxidation is electron loss and reduction is electron gain. An oxidizing agent accepts electrons and is itself reduced; a reducing agent donates electrons and is itself oxidized. Identify the change undergone by each reactant rather than relying on its name or the presence of oxygen. Electron accounting permits a metal-ion reaction to be recognized as redox even without molecular oxygen.
Apply it
In Zn + Cu2+ → Zn2+ + Cu, zinc loses electrons and copper ions gain them. Copper ions are the oxidizing agent, while zinc is the reducing agent.
Common pitfall: The oxidizing agent is reduced. Naming the agent after the change it undergoes reverses its role and can also reverse the assigned electron-transfer direction.
11.How do oxidation numbers reveal electron transfer?
Oxidation numbers provide a formal accounting system for recognizing redox changes. An increase indicates oxidation, while a decrease indicates reduction. Their sum equals the overall charge of a species, allowing an unknown value to be calculated from established assignments. These numbers are bookkeeping tools rather than direct measurements of charge on every atom.
Apply it
Iron changes from Fe2+ to Fe3+. Its oxidation number increases by one, indicating loss of one electron per iron ion. A balancing reduction must account for those electrons; the total electron loss and gain must agree.
Common pitfall: A change in a polyatomic species' overall charge does not identify the changing atom. Assign oxidation numbers before deciding which element is oxidized.
12.How does precipitation support qualitative identification?
A precipitation reaction forms a sparingly soluble solid when suitable dissolved ions are combined. The net ionic equation identifies the ions responsible and excludes spectators. A characteristic precipitate can support a qualitative identity test, but the reaction must be interpreted with its conditions and possible interfering ions. A visible solid alone does not uniquely identify an unknown substance.
Apply it
Aqueous silver nitrate and sodium chloride form silver chloride: Ag+ + Cl− → AgCl(s). Sodium and nitrate are spectators. In an unknown sample, precipitation requires appropriate controls and consideration of other precipitating anions.
Common pitfall: Precipitation need not involve redox. Silver and chloride retain their oxidation states when silver chloride forms, despite the obvious change in physical appearance.
Pharmacognosy/Biochemistry15%
13.Why do enzymes accelerate reactions without changing equilibrium?
Enzymes lower the activation-energy barrier, often through substrate positioning and transition-state stabilization. They do not change the overall free-energy difference between reactants and products or the equilibrium constant. Both reaction directions become kinetically accessible more quickly. Distinguish the rate of reaching equilibrium from the amount of product favored at equilibrium.
Apply it
A reversible reaction reaches the same final product proportion with and without an enzyme, but reaches it sooner with the enzyme. This supports a lowered activation barrier rather than a changed equilibrium constant.
Common pitfall: An enzyme cannot make an energetically unfavorable isolated reaction favorable merely by catalysis. Coupling is a separate mechanism with its own energy balance.
14.How does botanical identity differ from detection of one constituent?
Botanical identification asks whether the material is the declared plant preparation, whereas constituent testing asks whether a specified chemical is present or how much it contains. Goldenseal illustrates the distinction: berberine is a constituent, but detecting berberine alone does not establish that a commercial preparation contains authentic goldenseal. NCCIH reports products containing little goldenseal and undeclared ingredients. Identity assessment must discriminate the declared material from plausible substitutes.
Apply it
A product labeled goldenseal gives a positive result for berberine. Treat that as constituent evidence, then assess botanical identity with a suitable discriminating procedure and authenticated comparison material.
Common pitfall: One positive chemical marker cannot automatically establish species, plant part, preparation composition or freedom from substitution.
Herb-Drug Interactions: What the Science Says | NCCIH · FDA/ICH Q2(R2): Validation of Analytical Procedures, March 2024
15.How can increased substrate overcome competitive inhibition?
A reversible competitive inhibitor competes with substrate for access to the enzyme's active site. Raising substrate concentration can favor substrate binding under the ideal competitive model. Apparent Km increases, while Vmax remains attainable at sufficiently high substrate concentration. Reduced activity at one substrate concentration does not establish that maximum catalytic capacity has decreased.
Apply it
An inhibitor reduces rate at low substrate concentration, but sufficiently high substrate restores the original Vmax. This supports reversible competitive inhibition. Compare rates across substrate concentrations rather than interpreting a single inhibited measurement.
Common pitfall: Substrate rescue does not apply to every inhibitor. Loss of functional enzyme through irreversible inhibition cannot necessarily be overcome by more substrate.
16.Why is oxygen essential to the mitochondrial electron transport chain?
Oxygen is the terminal electron acceptor and is reduced to water. Electron transfer supports proton pumping across the inner mitochondrial membrane. Without oxygen, electron flow cannot continue normally, limiting regeneration of oxidized carriers and oxidative phosphorylation. Oxygen accepts electrons at the end of the chain; it does not directly donate phosphate to ADP.
Apply it
Removing oxygen from a mitochondrial preparation stops normal electron-transport-dependent ATP production. Restoring oxygen permits electron flow to resume if the machinery remains functional. The result connects oxygen availability with sustained electron transfer.
Common pitfall: Oxygen consumption and ATP synthesis are connected through electron transport and a proton gradient, but are different chemical steps.
17.How does a proton gradient drive ATP synthesis, and what does uncoupling change?
Electron transport moves protons toward the intermembrane space, establishing an electrochemical gradient. Their return to the matrix through ATP synthase supplies energy for ATP formation from ADP and inorganic phosphate. A proton leak dissipates the gradient without productive ATP synthesis. Electron transport and oxygen use can continue while ATP yield falls and more energy appears as heat.
Apply it
A hypothetical agent increases inner-membrane proton permeability. Continued oxygen consumption with decreased ATP yield supports uncoupling rather than complete inhibition of terminal electron transfer.
Common pitfall: Reduced ATP alone does not distinguish uncoupling from electron-transport inhibition. Examine oxygen consumption and the gradient as well as ATP production.
18.How do cranberry constituents connect plant chemistry with a proposed biological effect?
Cranberry contains proanthocyanidins, which are thought to inhibit bacterial attachment to the bladder wall. This proposed antiadhesion action differs from demonstrating bacterial killing or treating an established infection. Processing can reduce proanthocyanidin concentration, so different cranberry preparations need not deliver equivalent constituent exposure. Evidence for prevention must also be distinguished from evidence for treatment.
Apply it
Compare a cranberry preparation with documented constituent content against an unspecified processed product. Do not assume equivalent composition. A person with an existing symptomatic UTI requires assessment rather than substitution of cranberry for treatment.
Common pitfall: A proposed mechanism and a plant name do not establish efficacy for every preparation, population or clinical purpose.
19.How can St. John's wort reduce another medicine's systemic exposure?
St. John's wort induces relevant cytochrome P450 enzymes and intestinal P-glycoprotein. P-glycoprotein is an efflux transporter that moves substrates back toward the intestinal lumen. Increased metabolism and intestinal efflux can lower systemic exposure to susceptible drugs, including cyclosporine. The interaction direction depends on the affected drug and pathway; the herb can also produce separate pharmacodynamic interactions.
Apply it
A transplant patient starts St. John's wort and subsequently has lower cyclosporine concentrations despite unchanged prescribed dosing and adherence. Recognize induction of metabolism and intestinal efflux as a potentially serious explanation and coordinate prompt clinical assessment.
Common pitfall: Do not describe this decreased-exposure interaction as inhibition. Inhibiting the same metabolic and efflux pathways would generally favor increased exposure.
Herb-Drug Interactions: What the Science Says | NCCIH · NCCIH: St. John's Wort—Usefulness and Safety
20.What do ginsenosides teach about interpretation of plant preparations?
Asian ginseng contains multiple substances; ginsenosides, also called panaxosides, are considered important constituents. Naming a constituent group does not establish that every ginseng preparation has the same composition or clinical effects. NCCIH describes inconsistent findings for several uses and mixed findings for warfarin interactions. Distinguish chemical composition, evidence of benefit and interaction evidence when evaluating a botanical product.
Apply it
A product is advertised as containing ginsenosides. Assess what the preparation actually contains and what evidence applies to that preparation and intended use, rather than treating the constituent name as proof of efficacy.
Common pitfall: A named plant constituent is neither a universal efficacy guarantee nor proof that an interaction occurs in the same direction in every study.
21.Why can findings for an isolated constituent fail to establish effects of the whole plant preparation?
A constituent and the botanical preparation containing it can produce different systemic exposures. Goldenseal contains berberine, but NCCIH notes that very little berberine may be absorbed after oral goldenseal. Results from studies of berberine therefore cannot automatically be assigned to goldenseal. Goldenseal also inhibits CYP2D6 and CYP3A4, so limited exposure to one constituent does not establish absence of interactions from the preparation.
Apply it
A claim cites a berberine study to promote oral goldenseal. Examine whether the tested substance, preparation and exposure match. Separately assess CYP-mediated interaction risk.
Common pitfall: Do not substitute evidence about an isolated constituent for evidence about the whole product, or equate low constituent absorption with interaction-free use.
Practice of Pharmacy17.5%
22.How is percentage weight-in-volume converted to ingredient mass?
Percentage weight-in-volume expresses grams of solute in each 100 mL of final preparation. Multiply that ratio by the desired final volume. Keep the denominator as final preparation volume rather than the initial quantity of solvent. Converting to grams or milligrams per milliliter makes subsequent calculations explicit and permits a separate check of portion content.
Apply it
A hypothetical 1.5% w/v preparation in a final volume of 200 mL contains 3 g of solute, equivalent to 15 mg/mL. Adjust solvent to final volume after incorporating the solute.
Common pitfall: Adding solute to the full stated volume of solvent may exceed the intended final volume and produce a concentration different from the target.
OpenStax Chemistry 2e: Other Units for Solution Concentrations
23.How does molarity connect solution volume with amount of substance?
Molarity is moles of solute divided by liters of final solution. Multiply molarity by volume in liters to obtain moles, then multiply by molar mass if mass is required. Converting milliliters to liters prevents a factor-of-one-thousand error. The denominator describes the completed solution, and the molar mass must correspond to the chemical substance actually being measured.
Apply it
For 250 mL of a hypothetical 0.20 mol/L solution, the required amount is 0.050 mol. At a stated molar mass of 80 g/mol, this corresponds to 4.0 g.
Common pitfall: Multiplying molarity directly by a volume expressed in milliliters misuses the units. Write the conversion before evaluating the numerical result.
24.When does the dilution equation conserve solute?
C1V1 = C2V2 applies when dilution does not lose or chemically change the solute and compatible concentration units are used. Solute amount stays constant while final solution volume changes. Calculate the stock volume, then make the preparation up to the required final volume. Mixing two nonzero solute concentrations requires including both contributions rather than treating one stock as pure solvent.
Apply it
To prepare 100 mL of a 2% solution from a 10% stock, use 20 mL of stock and suitable diluent to a final volume of 100 mL.
Common pitfall: The final volume is not the amount of diluent to add. Adding 100 mL of diluent to 20 mL of stock gives a different concentration.
25.How is a prescribed mass converted to a liquid volume?
Divide required drug mass by the preparation's mass-per-volume concentration. First express both masses in matching units and verify the actual product concentration. A label expressed as milligrams per several milliliters can be converted to milligrams per milliliter before division. The resulting units should be milliliters, and multiplying the calculated volume by concentration should recover the required mass.
Apply it
A hypothetical required amount is 150 mg and the liquid contains 250 mg per 5 mL. The concentration is 50 mg/mL, so the required volume is 3 mL.
Common pitfall: The denominator volume on a label is not an automatic dose. It describes concentration and must be combined with the prescribed amount.
OpenStax Chemistry 2e: Other Units for Solution Concentrations
26.Why is density needed to convert weight percentage into a volume dose?
Percentage weight-in-weight gives grams of ingredient per 100 g of preparation. Density converts a measured preparation volume into preparation mass; applying the mass fraction then gives ingredient mass. Without a valid mass-volume relationship, a weight percentage cannot generally be interpreted as the same numerical weight-in-volume percentage. Keep the preparation mass distinct from the ingredient mass throughout the calculation.
Apply it
A hypothetical liquid is 5% w/w with density 1.10 g/mL. A 4 mL portion weighs 4.4 g and contains 0.22 g, or 220 mg, of ingredient.
Common pitfall: Assuming every liquid has density 1 g/mL silently changes a mass-based concentration into a volume-based one and can misstate the delivered amount.
OpenStax Chemistry 2e: Other Units for Solution Concentrations
27.How are two stock concentrations combined by mass balance?
For compatible solutions with additive volumes assumed, write C_highV_high + C_lowV_low = C_finalV_final and V_high + V_low = V_final. Both stocks contribute solute. A target made using only those stocks must lie between their concentrations, providing an immediate plausibility check. The concentration units must be compatible so that each concentration-volume product represents the same kind of solute quantity.
Apply it
Prepare 100 mL of a hypothetical 6% solution from 10% and 2% stocks. Equal 50 mL portions supply the required solute under the additive-volume assumption.
Common pitfall: Treating the weaker stock as pure diluent omits its solute. Also avoid assuming additive volumes when the stated preparation conditions do not support that model.
OpenStax Chemistry 2e: Molarity · OpenStax Chemistry 2e: Other Units for Solution Concentrations
28.How does dimensional analysis prevent daily-dose calculation errors?
Preserve the meaning of each quantity: amount per dose, doses per day, treatment days and concentration-based volume. Attach units to each factor. A total daily amount differs from an amount per administration; multiplying an already daily amount by frequency counts the schedule twice. Calculate total drug mass before converting to the volume required for the treatment period.
Apply it
A hypothetical order specifies 100 mg per dose, three doses daily for four days. The requirement is 1,200 mg. At 40 mg/mL, the calculated treatment quantity is 30 mL before any separately specified allowance.
Common pitfall: Establish whether the starting milligrams apply to each dose or the whole day before multiplying by frequency. Correct arithmetic cannot rescue an incorrectly interpreted starting quantity.
OpenStax Chemistry 2e: Other Units for Solution Concentrations
29.When must an ambiguous prescription be clarified?
Prescription interpretation is a professional dispensing responsibility under the Philippine Pharmacy Act. If medicine, strength or directions cannot be determined reliably, resolve the uncertainty before supplying the affected medicine. Available information can inform assessment but should not silently replace an unclear instruction. The decisive cue is unresolved information that could change what the patient receives or how it is used.
Apply it
A prescription could indicate either of two marketed strengths, and the patient's recollection is uncertain. Contact the prescriber and document the clarification before completing dispensing.
Common pitfall: A commonly used strength does not establish the prescriber's intent for this patient. Previous use can inform clarification but does not itself resolve a conflicting current instruction.
30.Which particulars must a dispensing label contain under section 36 of RA 10918?
Section 36 requires the patient's name; generic name of the medicine; brand name, if any; strength; expiry date; directions for use; pharmacy name and address; doctor's name; dispensing pharmacist's name; and applicable auxiliary labels. These are express statutory particulars. Additional requirements prescribed by the Board are a separate obligation and do not replace the listed information.
Apply it
Check a prepared label against every listed particular. A brand name and 'use as directed' do not resolve missing generic identification or replace explicit prescribed directions. Add applicable auxiliary instructions and the required identifying details before supply.
Common pitfall: Neither manufacturer packaging nor verbal counseling substitutes for the required patient-specific dispensing label.
REPUBLIC ACT NO. 10918 - AN ACT REGULATING AND MODERNIZING THE PRACTICE OF PHARMACY IN THE PHILIPPINES, REPEALING FOR THE PURPOSE REPUBLIC ACT NUMBERED FIVE THOUSAND NINE HUNDRED TWENTY-ONE (R.A. NO. 5921), OTHERWISE KNOWN AS THE PHARMACY LAW - Supreme Court E-Library · Republic Act No. 10918, Philippine Pharmacy Act
31.How should herbal products enter medication reconciliation?
Include prescription medicines, nonprescription products and herbal preparations because interaction risk depends on the full exposure history. Ask specifically about supplements, recording the product, timing and intended use. St. John's wort can reduce exposure to susceptible medicines through induction and can increase serotonin-related effects with serotonergic agents. Starting or stopping the product can therefore be relevant to assessment.
Apply it
A patient reports no new medicines but mentions a recently started herbal mood product. Identifying St. John's wort prompts targeted assessment of concurrent medicines and symptoms.
Common pitfall: A patient may not classify a supplement as medicine. A complete prescription list can still omit an important interaction, especially when supplements are not explicitly discussed.
NCCIH: St. John's Wort—Usefulness and Safety · Herb-Drug Interactions: What the Science Says | NCCIH · Republic Act No. 10918, Philippine Pharmacy Act
32.Why does dispensing require pharmacist professional oversight?
The Philippine Pharmacy Act establishes pharmacist responsibilities in dispensing and related activities. Dispensing includes prescription validation, interpretation, dose calculations, labeling, record keeping and counseling, beyond package transfer. Distinguish logistical assistance from decisions requiring pharmaceutical judgment. Assigning preparation tasks does not resolve a professional uncertainty or transfer the pharmacist's responsibility for that assessment.
Apply it
An assistant notices an unclear direction during preparation and refers it to the pharmacist. The pharmacist evaluates whether the uncertainty changes safe use, obtains clarification where needed and checks the resulting instructions before supply.
Common pitfall: Operational convenience does not determine professional scope. Accurate package assembly cannot resolve an underlying prescription interpretation problem or establish that counseling is complete.
Republic Act No. 10918, Philippine Pharmacy Act · REPUBLIC ACT NO. 10918 - AN ACT REGULATING AND MODERNIZING THE PRACTICE OF PHARMACY IN THE PHILIPPINES, REPEALING FOR THE PURPOSE REPUBLIC ACT NUMBERED FIVE THOUSAND NINE HUNDRED TWENTY-ONE (R.A. NO. 5921), OTHERWISE KNOWN AS THE PHARMACY LAW - Supreme Court E-Library
Pharmacology-Pharmacokinetics15%
33.How does first-pass metabolism affect bioavailability?
Systemic bioavailability is the fraction of a dose reaching systemic circulation unchanged. An oral dose may be incompletely absorbed and undergo intestinal or hepatic presystemic elimination. Intravenous administration provides complete systemic availability as the reference. Compare dose-normalized exposure rather than AUC alone when doses differ, assuming comparable clearance and an appropriate pharmacokinetic model.
Apply it
A hypothetical oral 100 mg dose has bioavailability 0.40. Approximately 40 mg reaches systemic circulation unchanged under the model. The remainder may reflect incomplete absorption, presystemic elimination or both.
Common pitfall: Absorption and systemic bioavailability are different. Absorbed drug can be removed before reaching systemic circulation unchanged, so low bioavailability does not uniquely identify poor absorption.
OpenStax Pharmacology for Nurses: Pharmacokinetics and Pharmacodynamics
34.How does distribution volume influence a theoretical loading dose?
Apparent distribution volume relates body drug amount to plasma concentration. In a simplified one-compartment model, theoretical loading dose equals target concentration multiplied by distribution volume and divided by bioavailability. A larger distribution volume requires more drug for the same target concentration. This addresses initial concentration; maintenance requirements depend primarily on clearance.
Apply it
For a hypothetical intravenous drug, target concentration 5 mg/L and distribution volume 20 L imply a model loading amount of 100 mg. This assumes no drug is already present and that the stated model applies.
Common pitfall: Apparent distribution volume is a proportionality term and need not equal an anatomical fluid volume. A model loading amount also does not specify a safe administration rate.
Canadian Society of Pharmacology and Therapeutics: Half-life · OpenStax Pharmacology for Nurses: Pharmacokinetics and Pharmacodynamics
35.Why does clearance govern maintenance input?
Clearance is the volume of plasma effectively cleared of drug per unit time. Under constant linear kinetics, elimination rate equals clearance multiplied by concentration. Average systemic input must match average elimination to preserve steady state. Administered extravascular input must also account for bioavailability. After dosing stops, constant first-order elimination leaves a fraction (1/2)^n after n half-lives.
Apply it
Clearance 3 L/h and target average concentration 2 mg/L require average systemic input 6 mg/h. At bioavailability 0.50, average administered input is 12 mg/h under the model.
Common pitfall: Clearance has volume-per-time units. Multiply by concentration to obtain a mass-per-time elimination rate; do not equate clearance directly with the drug amount removed.
Canadian Society of Pharmacology and Therapeutics: Half-life · OpenStax Pharmacology for Nurses: Pharmacokinetics and Pharmacodynamics
36.How do clearance and distribution determine first-order half-life?
For a one-compartment drug with constant first-order elimination, t½ = 0.693Vd/CL. Increasing distribution volume lengthens half-life if clearance is unchanged; increasing clearance shortens it if distribution is unchanged. With stable input, half-life also governs the fractional approach to steady state: four and five half-lives reach approximately 94% and 97% of the eventual concentration.
Apply it
Distribution volume 30 L and clearance 3 L/h give half-life approximately 6.93 hours. If clearance falls to 1.5 L/h with distribution unchanged, half-life doubles to approximately 13.9 hours.
Common pitfall: A longer half-life does not uniquely establish reduced clearance. Distribution volume and model validity also matter, especially when elimination is not adequately described by constant first-order kinetics.
Canadian Society of Pharmacology and Therapeutics: Half-life
37.Which neurotransmitter process is affected by methylphenidate?
Methylphenidate blocks reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their extracellular availability. This pharmacodynamic action differs from the formulation mechanism controlling how CONCERTA releases methylphenidate. A drug's transporter effects and its dosage form's delivery behavior answer different questions about the same treatment. The active substance identifies the pharmacologic action, while the particular product determines its administration instructions.
Apply it
When comparing immediate-release methylphenidate with CONCERTA, separate the shared active-drug mechanism from differences in release and exposure over time.
Common pitfall: Extended release does not name a neurotransmitter mechanism. Conversely, knowing reuptake inhibition does not determine whether a particular tablet can be crushed or divided.
38.How does vorapaxar's antiplatelet mechanism identify its therapeutic target?
Vorapaxar antagonizes protease-activated receptor-1, or PAR-1, involved in thrombin-mediated platelet activation. The cited clinical pharmacology review classifies it as an antiplatelet drug. Blocking a platelet activation receptor differs from inhibiting the formation of thrombin itself. Identify the affected target and pathway before assigning a drug to a broad antithrombotic category.
Apply it
A mechanism vignette specifies inhibition of thrombin-triggered platelet activation through PAR-1 antagonism. Recognize a platelet receptor mechanism rather than direct inhibition of thrombin's catalytic activity.
Common pitfall: An effect on thrombin-mediated signaling does not establish that the drug directly inhibits thrombin or every platelet activation pathway. The named target supplies the discriminating cue.
39.Which toxic effects does naloxone antagonize?
Naloxone is an opioid antagonist used to reverse opioid effects, including respiratory depression. Its target distinguishes it from antagonists of other sedative classes. A response supports an opioid contribution but does not eliminate the need to assess ventilation, coexposures or other causes of impaired consciousness. Adequate breathing, rather than wakefulness alone, is a decisive observation when evaluating respiratory reversal.
Apply it
Markedly depressed breathing after documented opioid exposure calls for emergency ventilatory support and opioid antagonism as indicated. Flumazenil addresses a different receptor system and does not substitute for naloxone.
Common pitfall: Naloxone is not a universal antidote for sedation. Persistent impairment can reflect coingestants or another cause, and initial improvement does not establish sustained reversal.
DailyMed: Naloxone Hydrochloride Injection Label · DailyMed: Flumazenil Injection Label
40.Why can respiratory depression recur after naloxone?
Naloxone's duration may be shorter than the opioid's duration. As antagonism wanes, clinically important opioid effects can recur despite initial improvement. The label requires continued surveillance and additional treatment as necessary. Initial reversal does not establish opioid elimination or remove the need for respiratory assessment and supportive care. The relevant comparison is the duration of antagonism against the persistence of the opioid effect.
Apply it
After naloxone improves breathing, a patient exposed to a longer-acting opioid develops slowing respiration again. Recognize possible recurrent opioid toxicity and continue emergency monitoring and treatment.
Common pitfall: Successful reversal and complete elimination are different events. Brief improvement alone cannot establish sustained safety or exclude a later return of respiratory depression.
41.Which contraindications and seizure risks are decisive when considering flumazenil?
Flumazenil antagonizes benzodiazepine effects. It is contraindicated when benzodiazepines are controlling a potentially life-threatening condition, such as status epilepticus, and in patients showing signs of serious cyclic antidepressant overdose, including wide-QRS dysrhythmia or seizures. Separately, benzodiazepine dependence creates withdrawal and seizure risk when antagonism abruptly removes benzodiazepine effects. These specific contraindications and dependence-related risks must be distinguished.
Apply it
A sedated patient has suspected cyclic antidepressant poisoning with a wide-QRS dysrhythmia. Recognize the flumazenil contraindication. In a different patient with long-term benzodiazepine dependence, recognize withdrawal-seizure risk even without that overdose pattern.
Common pitfall: Do not reduce the assessment to whether benzodiazepines contributed to sedation. Removing therapeutic seizure suppression or unmasking serious mixed-poisoning toxicity can be dangerous.
Pharmaceutics17.5%
42.How does a suspension differ from a true solution?
A true solution contains molecularly or ionically dispersed solute that does not settle under ordinary conditions. A suspension contains dispersed solid particles that can settle and create concentration gradients. For a suspension intended to be mixed before measurement, redispersibility determines whether a portion can represent the intended concentration. A visually uniform preparation immediately after mixing can still contain undissolved particles.
Apply it
A preparation develops sediment on standing. If instructed shaking restores uniformity, a representative portion can be measured according to product instructions. A persistent compact deposit requires assessment before measurement.
Common pitfall: Temporary uniformity does not prove dissolution, and shaking instructions do not establish that a poorly redispersing product remains acceptable or delivers a representative dose.
43.How do weighing, mixing, filling and labeling create different manufacturing risks?
Manufacturing includes distinct operations rather than one undifferentiated preparation step. Weighing establishes ingredient quantities; mixing distributes ingredients; filling apportions the preparation into containers; packaging and labeling connect the contents with their identity and instructions. An error at one stage can produce a different defect from an error at another. Investigation should trace the observed defect to relevant operations and records.
Apply it
For a low assay, examine ingredient quantities and relevant processing records. For a wrong label on otherwise correctly prepared contents, examine packaging and labeling operations. A later assay alone cannot resolve a labeling mix-up.
Common pitfall: A correct bulk assay does not establish correct fill quantity, package identity or labeling.
REPUBLIC ACT NO. 10918 - AN ACT REGULATING AND MODERNIZING THE PRACTICE OF PHARMACY IN THE PHILIPPINES, REPEALING FOR THE PURPOSE REPUBLIC ACT NUMBERED FIVE THOUSAND NINE HUNDRED TWENTY-ONE (R.A. NO. 5921), OTHERWISE KNOWN AS THE PHARMACY LAW - Supreme Court E-Library · FDA: Investigating Out-of-Specification Test Results for Pharmaceutical Production, May 2022
44.Which phase distinguishes an emulsion from a suspension?
An emulsion disperses droplets of one liquid in another immiscible liquid; a suspension disperses solid particles in a fluid. In an oil-in-water emulsion, water is continuous and oil forms droplets. The arrangement reverses in water-in-oil systems. The continuous phase surrounds the dispersed material and influences physical behavior. Identify the physical state of the dispersed material before naming the system.
Apply it
Oil droplets surrounded by a continuous aqueous phase form an oil-in-water emulsion. Insoluble solid crystals dispersed in that liquid would instead constitute a suspension component.
Common pitfall: Ingredient order or relative quantity alone does not establish the continuous phase. Determine the actual phase arrangement rather than relying on how the ingredients are listed.
45.How do surfactants help stabilize dispersed systems?
Surfactants have regions with different affinities for water and nonpolar material. They accumulate at interfaces and, in suitable systems, reduce interfacial tension and assist dispersion or emulsification. An appropriate interfacial arrangement helps maintain dispersed droplets, but surfactant presence does not guarantee permanent stability, chemical compatibility or antimicrobial preservation. Each of those properties requires its own assessment.
Apply it
A suitable emulsifier helps oil droplets remain dispersed in water. The resulting preparation still contains distinct phases rather than becoming a molecular solution, even when its appearance is uniform.
Common pitfall: Better dispersion is not complete dissolution. An emulsifier is also not automatically an effective preservative, so physical appearance cannot establish adequate microbial control.
46.How can mixing individually clear preparations cause a pharmaceutical incompatibility?
Combining dissolved components can form a sparingly soluble product and create a new solid phase. The resulting precipitation is a physical incompatibility with a chemical basis. A net ionic equation identifies the reacting species, while spectator ions remain dissolved. The compatibility of each preparation alone does not establish compatibility after mixing.
Apply it
A model mixture combines dissolved silver ions with chloride ions and forms AgCl(s). Recognize that the new solid changes the composition of the liquid phase and that shaking does not reverse the underlying incompatibility.
Common pitfall: Do not treat unexpected precipitation as an acceptable suspension merely because it can be temporarily dispersed. Redispersion does not restore the original dissolved composition.
OpenStax Chemistry 2e: Classifying Chemical Reactions · OpenStax Chemistry 2e: Colloids
47.Why must CONCERTA tablets remain intact?
The CONCERTA label requires swallowing tablets whole and prohibits chewing, dividing or crushing. Its release-controlling structure delivers methylphenidate over time. Alteration can compromise that delivery even when the nominal drug amount is retained. Apply the instruction to the identified product; the active ingredient alone does not determine whether manipulation is acceptable.
Apply it
A patient cannot swallow CONCERTA and asks to crush it into food. Explain the intact-tablet requirement and coordinate a suitable alternative formulation with the prescriber rather than recommending an unsupported manipulation.
Common pitfall: Preserving the nominal milligram amount does not preserve the release behavior of a damaged extended-release tablet. Taking both divided pieces does not resolve that formulation problem.
48.What does an empty CONCERTA shell in stool indicate?
Nonabsorbable CONCERTA tablet components can pass in stool after drug release. A tablet-like shell is therefore compatible with normal delivery-system operation. Appearance alone does not prove that the dose remained unreleased, because the residual structure and the delivered medicine are different parts of the dosage form. Loss of effect or other symptoms still require assessment.
Apply it
A patient taking CONCERTA correctly reports a shell in stool without a change in effect. Explain the expected phenomenon and discourage an extra dose based only on its appearance.
Common pitfall: A recognizable residual structure is not necessarily an undelivered dose. Automatically repeating treatment can increase exposure rather than correct a demonstrated delivery failure.
49.Why must manufacturing investigation extend beyond a failed test?
An out-of-specification result can reflect laboratory error, manufacturing problems or another assignable cause. If laboratory review does not establish an explanation, examine relevant production processes and records. Consider whether ingredient quantities, distribution during mixing or other documented operations could explain the pattern. Testing detects a possible defect but does not independently identify its origin.
Apply it
A batch fails assay without an established laboratory error. Review relevant manufacturing records and the adequacy of sampling rather than assuming a later passing result proves the process was satisfactory.
Common pitfall: A selected passing sample cannot establish uniformity throughout a batch or explain an unresolved original failure. Preserve the full result pattern when evaluating possible causes.
FDA: Investigating Out-of-Specification Test Results for Pharmaceutical Production, May 2022
50.Why do assay and dissolution answer different dosage-form questions?
Assay measures drug content, whereas dissolution testing evaluates drug entering a specified medium under defined test conditions. A tablet can contain the expected amount while releasing it differently. Medium, apparatus and operating conditions belong to the dissolution procedure and must support its intended discriminatory purpose. The cited vorapaxar review separately evaluates dissolution method, acceptance criteria and formulation bridging.
Apply it
Two tablet batches have similar assay results but different dissolution profiles. Investigate release performance and relevant formulation or process differences rather than treating equal content as proof of equal release.
Common pitfall: A dissolution result is not itself a direct measurement of systemic bioavailability, and a passing assay cannot substitute for required release testing.
51.How do sections 33 and 30 of RA 10918 address different dispensing requirements?
Section 33 requires a valid prescription for prescription medicines. Section 30 separately addresses pharmacist availability: its emergency exception applies when a pharmacist's services are unavailable and requires reporting to the supervising pharmacist within 24 hours. Section 5 defines emergency cases as life-threatening situations requiring immediate medical attention and treatment, including epidemics or natural calamities. Section 30 does not establish a waiver of section 33's prescription requirement.
Apply it
For routine supply of a prescription-only medicine, prior use or a small requested quantity does not replace a valid prescription. In an emergency involving pharmacist unavailability, assess section 30's conditions and reporting duty separately from prescription authorization.
Common pitfall: Do not turn an exception concerning pharmacist unavailability into a general emergency permission to dispense prescription medicines without a valid prescription.
REPUBLIC ACT NO. 10918 - AN ACT REGULATING AND MODERNIZING THE PRACTICE OF PHARMACY IN THE PHILIPPINES, REPEALING FOR THE PURPOSE REPUBLIC ACT NUMBERED FIVE THOUSAND NINE HUNDRED TWENTY-ONE (R.A. NO. 5921), OTHERWISE KNOWN AS THE PHARMACY LAW - Supreme Court E-Library · Republic Act No. 10918, Philippine Pharmacy Act
Quality Control/Quality Assurance15%
52.How does chromatographic specificity protect an assay from interference?
Chromatography separates sample components before their responses are evaluated. Specificity requires assessing the intended analyte in the presence of relevant impurities, degradation products and matrix components. If another component coelutes and contributes to the drug signal, consistent peak measurement does not establish a specific assay. Challenge the separation with components relevant to the procedure's intended use.
Apply it
A degradation product overlaps the drug peak and increases reported content. This is a specificity concern even if repeated injections give nearly identical areas.
Common pitfall: A clean solvent blank and good calibration in pure standards do not exclude interference in actual samples. Repeatable measurement of a combined signal can remain analytically misleading.
FDA/ICH Q2(R2): Validation of Analytical Procedures, March 2024
53.How does accuracy differ from tightly grouped results?
Accuracy concerns agreement with an accepted reference value; precision concerns agreement among repeated measurements. Results can be tightly grouped yet systematically biased. Assess accuracy using a suitable reference comparison or recovery design across the intended range. Evaluate precision separately from the scatter among independent measurements under specified conditions. A reproducible calibration error can shift every result in the same direction.
Apply it
A reference containing 100 units repeatedly gives approximately 94 units with little variation. The results support precision under those conditions but reveal negative bias relative to the reference.
Common pitfall: A small standard deviation cannot rule out systematic calibration or recovery error. Repeating the same biased procedure more often does not, by itself, improve accuracy.
FDA/ICH Q2(R2): Validation of Analytical Procedures, March 2024
54.Which precision level matches the source of variation?
Repeatability concerns closely matched conditions over a short interval. Intermediate precision examines within-laboratory changes such as analysts, days or equipment. Reproducibility addresses between-laboratory variation where applicable. Select the level corresponding to the variability being evaluated and identify whether the experiment includes sample preparation or only instrumental measurement. The scope of the experiment limits the precision claim it supports.
Apply it
Independent preparations measured by different analysts on different days in one laboratory assess intermediate precision. Repeated injections from one vial address a narrower instrumental source of variation.
Common pitfall: Injection repeatability does not automatically establish precision of the complete sample-preparation procedure. Likewise, within-laboratory agreement does not demonstrate agreement between laboratories.
FDA/ICH Q2(R2): Validation of Analytical Procedures, March 2024
55.What must instrumental calibration and its lower reporting limit establish?
Calibration connects instrumental response with analyte concentration or amount. The model must support suitable performance across the intended reportable range; a high correlation statistic alone is insufficient. Detection establishes distinguishable presence, whereas quantitation requires suitable quantitative performance. A visible chromatographic peak can therefore be detectable without supporting a reliable numerical concentration.
Apply it
Dilute an above-range sample only under justified, supported procedure conditions. For a trace impurity near the lower limit, establish quantitative performance before reporting a numerical result.
Common pitfall: Neither extrapolating a straight-looking calibration line nor adding decimal places supplies missing analytical performance. Reported numerical detail must remain consistent with demonstrated measurement capability.
FDA/ICH Q2(R2): Validation of Analytical Procedures, March 2024
56.Why do bacterial spores matter when evaluating microbial control?
Bacterial spores are resistant survival forms and are a decisive boundary between high-level disinfection and sterilization. High-level disinfection can eliminate vegetative bacteria, mycobacteria, fungi and viruses under suitable conditions but may not eliminate large numbers of bacterial spores. Demonstrating activity against an easier-to-inactivate organism does not establish a sporicidal outcome. Organism type and demonstrated process performance must both inform the claim.
Apply it
A process demonstrates elimination of vegetative bacteria but has no supported sporicidal performance. Do not classify it as sterilization on that evidence.
Common pitfall: The word antibacterial does not establish equal effectiveness against vegetative cells and spores. A broad product description cannot replace evidence for the required microbial-control outcome.
57.What should follow an initial out-of-specification result?
Preserve original data and begin a timely, documented, scientifically sound investigation. Examine calculations, preparations, instruments and observations without presuming analyst error. Invalidate a result only with an adequately supported explanation. If laboratory error is not established, investigate broader causes. Further testing must answer defined questions under a justified plan rather than merely increase the number of passing results.
Apply it
An assay is below specification. Retain the records and review possible causes. A passing repeat without an explanation does not erase the original result or end the investigation.
Common pitfall: Unexpected does not mean invalid. Repeating until acceptable results predominate is testing into compliance and can conceal evidence of an actual batch problem.
FDA: Investigating Out-of-Specification Test Results for Pharmaceutical Production, May 2022
58.Which statutory conditions govern pharmacist administration of adult vaccines?
RA 10918 section 4(g) covers administration of FDA-approved adult vaccines and requires training in safe administration and management of adverse events following immunization (AEFI), with a certificate issued by a PRC-accredited institution. Section 5(b) defines adult vaccines for patients aged 18 years and above, listing cervical cancer, influenza, pneumococcal and other pre-exposure prophylactic vaccines, with other vaccines subject to DOH definition. Section 40 additionally requires a doctor's prescription no more than seven days old and monthly vaccination and AEFI reports to DOH regional offices.
Apply it
Before administration, verify vaccine approval and applicability under the adult-vaccine definition, patient age, the pharmacist's required training certificate and a doctor's prescription no more than seven days old. Ensure preparedness to manage AEFI and arrange monthly submission of vaccination and AEFI reports to the DOH regional office.
Common pitfall: Age eligibility, vaccine approval and training alone do not satisfy all statutory conditions. The recent prescription and monthly reporting duties are additional requirements; this provision does not authorize unrestricted pediatric vaccination.
59.Why is high-level disinfection different from sterilization?
Sterilization eliminates all forms of microbial life, including bacterial spores, when properly applied. High-level disinfection may not eliminate large numbers of spores. Process selection must match intended use and contamination risk. Cleaning is essential because retained material can interfere with subsequent disinfection or sterilization. The required outcome depends on where the item will contact the patient, as well as compatibility with the process.
Apply it
An instrument will enter sterile tissue. High-level disinfection alone does not establish the required sterilization outcome. Select a compatible sterilization process and perform the necessary cleaning first.
Common pitfall: Visible cleanliness cannot establish sterility, and a strong chemical treatment is not automatically a sterilization process. Evaluate the demonstrated process outcome rather than perceived strength.
60.How does intended contact determine reprocessing level?
Critical items enter sterile tissue or the vascular system and require sterilization. Semicritical items contact mucous membranes or nonintact skin and generally require at least high-level disinfection. Noncritical items contact intact skin and require an appropriate lower-level process. This risk classification connects microbial control with prevention of infection transmission. Cleaning remains a necessary preparatory step rather than a substitute for the required reprocessing level.
Apply it
An instrument entering sterile tissue and a device touching intact skin require different processing levels. Classify patient contact first, then select compatible cleaning and reprocessing procedures.
Common pitfall: Physical resemblance between devices does not establish equal reprocessing requirements. Intended contact determines the risk category; appearance alone does not establish microbial safety.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Connect medicinal-chemistry scaffolds, stereochemistry and metabolic transformations with drug identity and behavior; use reaction conditions to predict hydrolysis, redox and precipitation.
- Distinguish botanical identity, constituent content, preparation-specific exposure and clinical evidence using goldenseal, ginseng and cranberry examples.
- Practise concentration, dilution and mixture calculations with written units, explicit final-volume assumptions and independent mass-balance checks.
- Separate drug targets from delivery mechanisms, and distinguish bioavailability, distribution, clearance and half-life before selecting an equation.
- Trace manufacturing operations from ingredient quantities through mixing, filling and labeling; distinguish content testing from release performance and identify precipitation incompatibilities.
- Interpret chromatographic separation, accuracy, precision and calibration alongside original analytical data and scientifically justified investigations.
- Apply Philippine labeling, prescription and vaccination criteria; connect microbial resistance and patient-contact categories with infection-prevention decisions.
- Use the official PRC outline as the full scope and extend study beyond these selected foundations within every listed subject.
A practical preparation plan
1. Map the complete PRC scope
Create a six-subject study map from the official outline. Mark the topics addressed by these selective lessons and identify remaining topics for further study.
2. Build calculation fluency
Work concentration, dilution, mixture and pharmacokinetic problems without answer options. Write units, identify assumptions and estimate whether each result is plausible before checking arithmetic.
3. Explain the decisive mechanism
For each lesson, identify the mechanism and a cue distinguishing it from an alternative. Practise metabolic induction versus inhibition, active-drug action versus release control, and assay content versus dissolution.
4. Apply explicit decision criteria
Check dispensing labels against statutory particulars, separate prescription authorization from pharmacist-availability exceptions, and distinguish antidote contraindications from other risk factors.
5. Use the drills diagnostically
Complete the questions, explain why each alternative is less appropriate and classify errors as knowledge, interpretation or calculation problems. Use spaced flashcard recall and return to the complete outline; drill performance is not a pass prediction.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- PRC: Program of the Pharmacists Licensure Examination, October 15 and 16, 2026
- PRC Downloads
- PRC: 2026 Schedule of Examination
- PRC: Program of the Pharmacists Licensure Examination, April 18 and 19, 2026
- Republic Act No. 10918, Philippine Pharmacy Act
- OpenStax Chemistry 2e: Buffers
- OpenStax Organic Chemistry: Chemistry of Esters
- OpenStax Organic Chemistry: Enantiomers and the Tetrahedral Carbon
- OpenStax Chemistry 2e: Classifying Chemical Reactions
- OpenStax Biology 2e: Enzymes
- OpenStax Biology 2e: Oxidative Phosphorylation
- NCCIH: St. John's Wort—Usefulness and Safety
- OpenStax Chemistry 2e: Molarity
- OpenStax Chemistry 2e: Other Units for Solution Concentrations
- Canadian Society of Pharmacology and Therapeutics: Half-life
- OpenStax Pharmacology for Nurses: Pharmacokinetics and Pharmacodynamics
- DailyMed: Naloxone Hydrochloride Injection Label
- DailyMed: Flumazenil Injection Label
- DailyMed: CONCERTA Extended-release Tablet Label
- OpenStax Chemistry 2e: Colloids
- FDA/ICH Q2(R2): Validation of Analytical Procedures, March 2024
- FDA: Investigating Out-of-Specification Test Results for Pharmaceutical Production, May 2022
- CDC: A Rational Approach to Disinfection and Sterilization
- REPUBLIC ACT NO. 10918 - AN ACT REGULATING AND MODERNIZING THE PRACTICE OF PHARMACY IN THE PHILIPPINES, REPEALING FOR THE PURPOSE REPUBLIC ACT NUMBERED FIVE THOUSAND NINE HUNDRED TWENTY-ONE (R.A. NO. 5921), OTHERWISE KNOWN AS THE PHARMACY LAW - Supreme Court E-Library
- Herb-Drug Interactions: What the Science Says | NCCIH
- Enzyme Kinetics 4 to 6
- 019211s040lbl.pdf
- 204886Orig1s000ClinPharmR.pdf
- DailyMed - FLUMAZENIL injection, solution
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.